Streetbeat News

Regulatory

OKYO

OKYO Pharma Limited's drug candidate, OK-101, currently in a phase 2 trial for dry eye disease (DED), is showing a positive safety profile. The trial involves 240 patients, with 95% having completed four weeks of dosing. The company expects the last patient's last visit to occur in November 2023, with top-line data to be released in December 2023. DED affects approximately 49 million people in the US. OKYO shares are down 17.60% at $2.29.

Portfolio Pulse from Vandana Singh

October 05, 2023 | 2:27 pm

CLNN

Clene Inc. (NASDAQ:CLNN) has been awarded a $45.1 million grant from the National Institute of Neurological Disorders and Stroke (NINDS) to support an Expanded Access Protocol (EAP) for its investigational drug, CNM-Au8, in amyotrophic lateral sclerosis (ALS). The grant will fund a four-year study in collaboration with Columbia University and Synapticure. The EAP will allow ALS patients who don't meet the criteria for clinical trials to access CNM-Au8. Clene has shown evidence of consistent safety and improved survival for CNM-Au8 in two independent Phase 2 trials and an ongoing EAP.

Portfolio Pulse from Benzinga Newsdesk

October 05, 2023 | 2:02 pm

AMZN

BKE

CAG

CLX

DELL

DIS

DOV

MRK

MSFT

PSNY

STZ

VFS

Disney reduces ticket prices for children due to attendance slump. Amazon discontinues its live-audio app, Amp. US government to stop free distribution of Merck's COVID-19 pill. UK regulators investigate Amazon and Microsoft's dominance in cloud computing. Dell to update its long-term financial framework. Dover acquires FW Murphy for $530M. Constellation Brands reports Q2 net sales growth of 7%. Polestar Automotive reports Q3 delivery growth of 50%. VinFast Auto reports Q3 revenues of $342.66 million. Clorox shares fall after reporting preliminary Q1 FY24 financial results. ConAgra Brands reports flat Q1 FY24 sales. Buckle Inc reports 11.1% drop in comparable store sales for September.

Portfolio Pulse from Vandana Singh

October 05, 2023 | 2:01 pm

SPY

VGK

Russian President Vladimir Putin has stated that the conflict in Ukraine is not about territories, but about the global order. He also mentioned that the West always needs an enemy. This statement could potentially impact global markets and ETFs like SPY and VGK.

Portfolio Pulse from Benzinga Newsdesk

October 05, 2023 | 1:59 pm

LGVN

Longeveron has filed a U.S. patent application (#20230310509) for the treatment of Alzheimer's disease with allogeneic mesenchymal stem cells.

Portfolio Pulse from Charles Gross

October 05, 2023 | 1:46 pm

AMZN

MSFT

The UK's anti-competition regulators have initiated an investigation into the dominance of Microsoft Corp (MSFT) and Amazon.Com Inc (AMZN) in the cloud computing market. The investigation, led by media watchdog Ofcom and the Competition and Markets Authority (CMA), will focus on the companies' control over the market and its impact on competition and business operations. AWS and Azure, the cloud services of Amazon and Microsoft respectively, command 60% to 70% of the cloud expenditure. The investigation is expected to conclude by April 2025.

Portfolio Pulse from Anusuya Lahiri

October 05, 2023 | 1:40 pm

LNVGY

The U.S. International Trade Commission (USITC) has announced an investigation into certain electronic devices made by Lenovo and Motorola Mobility. This follows a complaint filed by InterDigital, a mobile technology research and development company.

Portfolio Pulse from Benzinga Newsdesk

October 05, 2023 | 1:25 pm

AGNG

FHLC

FXH

IYH

VHT

The FDA has proposed a regulatory shift that would require lab-developed tests to be reviewed before they can be sold. This move has created uncertainty in the laboratory-testing market, potentially affecting startups that are developing tests to detect diseases earlier and personalize treatments. The FDA's concerns are based on the efficacy of lab-developed tests, which have led to over- or under-treatment for heart disease, inappropriate therapies, and incorrect diagnoses of diseases, including Alzheimer's.

Portfolio Pulse from Vandana Singh

October 05, 2023 | 1:06 pm

GOVX

GeoVax Labs, Inc. (NASDAQ:GOVX) has received a Notice of Allowance for Patent Application No. 17/409,574 titled 'Multivalent HIV Vaccine Boost Compositions and Methods of Use' from the U.S. Patent and Trademark Office. The patent covers a priming vaccination with a DNA vector encoding multiple HIV antigens in virus-like particles (VLPs), followed by a boost vaccination with GeoVax's vector platform for expressing HIV-1 antigens in VLPs utilizing an MVA viral vector. The company's HIV program forms an important part of the dataset underpinning all of its MVA-based development programs.

Portfolio Pulse from Benzinga Newsdesk

October 05, 2023 | 1:01 pm

MRK

PFE

The US government will stop distributing free doses of Merck's COVID-19 antiviral treatment, Lagevrio, by mid-November, shifting its availability to the commercial market. The drug's commercial distribution is contingent upon an updated letter of authorization from the FDA. Merck's drug has faced competition from Pfizer's Paxlovid, which has a higher effectiveness rate. Merck's shares are down 0.39% premarket.

Portfolio Pulse from Vandana Singh

October 05, 2023 | 1:00 pm